Expertise in
11
conditions

Dr. Lorinda Chung

Rheumatology
Stanford Hospital And Clinics
300 Pasteur Dr, 
Stanford, CA 
Expertise in
11
conditions
Stanford Hospital And Clinics
300 Pasteur Dr, 
Stanford, CA 

Overview

Lorinda Chung is a Rheumatologist in Stanford, California. Dr. Chung is highly rated in 11 conditions, according to our data. Her top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Dermatomyositis, and Polymyositis.

Her clinical research consists of co-authoring 180 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Rheumatology

Licenses

Internal Medicine in CA

Hospital Affiliations

Stanford Health Care

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Plan of San Mateo
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Stanford Hospital and Clinics
300 Pasteur Dr, Stanford, CA 94305
Other Locations
Palo Alto VA Medical Center
3801 Miranda Ave, Palo Alto, CA 94304

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Iloprost
Study Phase: Phase 3
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: August 30, 2023
Intervention Type: Drug
Study Drug: Belumosudil (KD025)
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Other, Biological, Drug, Diagnostic test
Study Phase: Phase 2
A Multi-center, Randomized, Double-blind (Sponsor Open), Placebo-controlled, Repeat-dose, Proof of Mechanism Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Explore Efficacy of GSK2330811 in Participants With Diffuse Cutaneous Systemic Sclerosis
A Multi-center, Randomized, Double-blind (Sponsor Open), Placebo-controlled, Repeat-dose, Proof of Mechanism Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Explore Efficacy of GSK2330811 in Participants With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Completed
Publish Date: May 24, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: March 29, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
Use of FLIP Topography to Evaluate Esophageal Symptoms in Patients With Scleroderma
Use of FLIP Topography to Evaluate Esophageal Symptoms in Patients With Scleroderma
Enrollment Status: Withdrawn
Publish Date: January 20, 2021
Intervention Type: Device, Procedure
Study Phase: Not Applicable
View 6 Less Clinical Trials

180 Total Publications

Type III and type VI collagen neoepitopes are associated with disease severity in systemic sclerosis.
Type III and type VI collagen neoepitopes are associated with disease severity in systemic sclerosis.
Journal: The Journal of rheumatology
Published: November 15, 2025
Similar Doctors
Vibeke Strand
Expertise in
13
conditions
Dr. Vibeke Strand
Rheumatology
Expertise in
13
conditions
Dr. Vibeke Strand
Rheumatology

Office

306 Ramona Rd, 
Portola Valley, CA 
 (6.2 miles away)
650-529-0150
Languages Spoken:
English
See accepted insurances

Vibeke Strand is a Rheumatologist in Portola Valley, California. Dr. Strand is highly rated in 13 conditions, according to our data. Her top areas of expertise are Arthritis, Rheumatoid Arthritis (RA), Psoriatic Arthritis, Psoriasis, and Tissue Biopsy.

Mark Genovese
Expertise in
8
conditions
Dr. Mark Genovese
Rheumatology
Expertise in
8
conditions
Dr. Mark Genovese
Rheumatology

Stanford Hospital And Clinics

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-6961
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Genovese is a Rheumatologist in Stanford, California. Dr. Genovese is highly rated in 8 conditions, according to our data. His top areas of expertise are Rheumatoid Arthritis (RA), Arthritis, Psoriatic Arthritis, and Psoriasis.

Lianne Gensler
Expertise in
11
conditions
Dr. Lianne Gensler
Rheumatology
Expertise in
11
conditions
Dr. Lianne Gensler
Rheumatology

Ankylosing Spondylitis Clinic

400 Parnassus Ave., Floor B1, 
San Francisco, CA 
 (27.6 miles away)
415-353-2497
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Lianne Gensler is a rheumatologist and serves as director of the UCSF Ankylosing Spondylitis Clinic, which is dedicated to care for this inflammatory disease. Gensler's primary research interest is the disease progression of axial spondyloarthritis (a category that includes ankylosing spondylitis). Her research also seeks to identify predictors of osteoporosis development in patients with systemic lupus erythematosus. Gensler earned her medical degree at the University of California, Irvine. She completed an internal medicine residency, chief residency and rheumatology fellowship at UCSF, and subsequently joined the medical staff in the rheumatology program. Dr. Gensler is highly rated in 11 conditions, according to our data. Her top areas of expertise are Ankylosing Spondylitis, Axial Spondyloarthritis (AxSpA), Arthritis, and Rheumatoid Vasculitis.

Frequently Asked Questions about Dr. Lorinda Chung

How do I make an appointment with Dr. Lorinda Chung?

You can book an appointment with Dr. Lorinda Chung by calling their office at 650-723-6961. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lorinda Chung a top-rated expert for Scleroderma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lorinda Chung is classified as an Elite expert for Scleroderma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lorinda Chung specialize in?

While Dr. Lorinda Chung is a Rheumatology, they have specific expertise in Scleroderma, Systemic Sclerosis (SSc), and Dermatomyositis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Lorinda Chung participate in research or clinical trials?

Yes. Dr. Lorinda Chung has published 180 articles and abstracts on conditions like Scleroderma. You can view a list of Dr. Lorinda Chung's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Lorinda Chung accept my insurance?

Dr. Lorinda Chung accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 650-723-6961 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chung's expertise for a condition
ConditionClose
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile